Drugs / Panitumumab
Panitumumab
also known as
ABX-EGF · Vectibix · Pmab · Vectibix (Panitumumab) · AMG 954 · EU-Vectibix · PAN · panitumumab: Vectibix · +3 more
Monoclonal antibody targets EGFR
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | VECTIBIX | — | 2008-06-23 – 2025-01-16 | fda.gov ↗ |
| Approved | EU (EMA) | Vectibix | — | 2007-12-03 | europa.eu ↗ |
| Approved | US (FDA) | VECTIBIX | — | 2006-09-27 | fda.gov ↗ |
Trials 217 · started per year
today
US approved 2006
EU approved 2007
1
5
3
7
2
10
11
12
18
34
19
8
7
6
5
6
6
8
9
5
3
2
6
9
7
5
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05183048 | Feb 2023 → Feb 2028 expected | head and neck squamous cell carcinoma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 125 trials | ||||||
| Phase 1 | NCT07859085 | Oct 2026 → Mar 2029 expected | colorectal neoplasm, pancreatic ductal adenocarcinoma | Genentech, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07094113 | Jul 2025 → Apr 2028 expected | — | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT07094204 | Jul 2025 → Nov 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Astellas Pharma Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06983743 | Jun 2025 → May 2028 expected | metastatic neoplasm | Erasca, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06194877 | Apr 2024 → Mar 2025 | colorectal cancer, pancreatic ductal adenocarcinoma | MapKure, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05901545 | Aug 2023 → Nov 2028 expected | head and neck squamous cell carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04840472 | Mar 2021 → Mar 2027 | head and neck cancer | Stanford University | Suspended | No outcome recorded |
| Phase 1 | NCT04163952 | Jan 2020 → Mar 2025 | skin squamous cell carcinoma | Rutgers, The State University of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04185883 | Dec 2019 → Dec 2026 expected | cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03360734 | Nov 2017 → May 2020 | cancer | Glycotope GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02199223 | Jun 2014 → May 2016 | colorectal cancer | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02008383 | Jan 2014 → May 2018 | colorectal cancer | John Strickler, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT01791309 | Jan 2013 → Mar 2015 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01061788 | Apr 2010 → Dec 2018 | non-small cell lung carcinoma | Jeffrey Clarke | Completed | No outcome recorded |
| Phase 1 | NCT00879385 | Dec 2009 → Jan 2013 | colorectal cancer | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT00563316 | Mar 2008 → Mar 2009 | colorectal cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00610948 | Mar 2008 → May 2013 | cancer of unknown primary site | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00658658 | Mar 2008 → Mar 2015 | cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00586443 | Nov 2007 → Sep 2014 | cancer | Herbert Hurwitz, MD | Completed | No outcome recorded |
| Phase 1 | NCT00513383 | Apr 2006 → Oct 2010 | head and neck squamous cell carcinoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00352950 | Mar 2006 → Feb 2008 | non-small cell lung carcinoma | Amgen | Withdrawn | No outcome recorded |
| Phase 1 | NCT00101907 | Dec 2004 → Jun 2007 | esophageal cancer, lung cancer, malignant pancreatic neoplasm | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT00101894 | Dec 2004 → Apr 2010 | colon carcinoma, rectal carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00091806 | Aug 2004 → Apr 2006 | neoplasm | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00004879 | Apr 2000 → Jul 2005 | colorectal cancer, esophageal cancer, kidney cancer, lung cancer +2 | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/218 trials · 1 missed | ||||||
| Phase 1/2 | NCT05121038 | Oct 2021 → Sep 2025 overdue | colon carcinoma, malignant pancreatic neoplasm | Anup Kasi | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03764137 | Mar 2019 → Jan 2025 | malignant colon neoplasm | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03428958 | Oct 2018 → Mar 2024 | colorectal carcinoma | NuCana plc | Completed | No outcome recorded |
| Phase 1/2 | NCT03510208 | May 2018 → Nov 2026 expected | brain cancer, malignant glioma | Stanford University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01581840 | Jan 2016 → Sep 2018 | anal carcinoma, squamous cell carcinoma | Federation Francophone de Cancerologie Digestive | Completed | Missed primary |
| Phase 1/2 | NCT02613221 | Dec 2015 → Oct 2017 | colorectal cancer | Takeda | Completed | No outcome recorded |
| Phase 1/2 | NCT01927341 | Nov 2013 → Jan 2016 | colorectal cancer | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT01750918 | Dec 2012 → Jun 2020 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01591421 | Sep 2012 → Sep 2015 | colorectal cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01504477 | Dec 2011 → Feb 2014 | colorectal cancer | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01175733 | Jul 2010 → Mar 2016 | malignant pancreatic neoplasm | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 1/2 | NCT01139138 | Jun 2010 → Aug 2015 | colorectal carcinoma | The Queen Elizabeth Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01128387 | May 2010 → Oct 2016 | cancer | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00788957 | Oct 2008 → Jul 2010 | colon carcinoma, rectal cancer | NantBioScience, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00667420 | Apr 2008 → Jun 2011 | esophageal adenocarcinoma, gastric adenocarcinoma | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00630786 | Jan 2008 → May 2009 | colon carcinoma, rectal cancer | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00578071 | Dec 2007 → Jul 2011 | esophageal cancer | Brian Czito | Completed | No outcome recorded |
| Phase 1/2 | NCT00094835 | Jan 2005 → Mar 2007 | non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 2146 trials · 13 met primary · 16 missed | ||||||
| Phase 2 | NCT07659795 | Jul 2026 → Jun 2027 expected | colorectal cancer | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07644559 | Jun 2026 → Jun 2027 expected | pancreatic ductal adenocarcinoma | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07172919 | Jan 2026 → Jan 2028 expected | — | Amgen | Recruiting | No outcome recorded |
| Phase 2 | NCT07124884 | Aug 2025 → Jun 2030 expected | acute myeloid leukemia, KRAS gene mutation, colorectal carcinoma | Federation Francophone de Cancerologie Digestive | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06820463 | Apr 2025 → Mar 2028 expected | colorectal cancer | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06978400 | Mar 2025 → Nov 2027 expected | neoplasm | Blokhin's Russian Cancer Research Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06967155 | Mar 2025 → Nov 2027 expected | neoplasm | Blokhin's Russian Cancer Research Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06268015 | Nov 2024 → Jul 2028 expected | colorectal cancer | Nicholas DeVito, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06575127 | Aug 2024 → Sep 2025 overdue | colorectal cancer | Al-Azhar University | Recruiting | No outcome recorded |
| Phase 2 | NCT05638295 | Aug 2024 → Dec 2028 expected | metastatic malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Show all 146 trials opens the full record — a long page | ||||||
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00647530 | May 2008 → Dec 2016 | colorectal cancer | University of Birmingham | Unknown | Met primary |
| Phase 324 trials · 6 met primary · 5 missed | ||||||
| Phase 3 | NCT06998940 | May 2026 → Dec 2029 expected | pancreatic adenocarcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT06490536 | Oct 2024 → Mar 2026 overdue | colorectal cancer | IFOM ETS - The AIRC Institute of Molecular Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06252649 | Jul 2024 → Sep 2028 expected | colorectal cancer | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06509126 | Jun 2024 → Jan 2028 expected | colorectal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 3 | NCT06226857 | Jan 2024 → Dec 2026 expected | colorectal neoplasm | City Clinical Oncology Hospital No 1 | Recruiting | No outcome recorded |
| Phase 3 | NCT05198934 | Apr 2022 → Jul 2025 | colorectal cancer | Amgen | Completed | Met primary |
| Phase 3 | NCT03635021 | Oct 2018 → Jun 2025 overdue | colorectal cancer | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03300609 | Feb 2018 → Oct 2019 | colorectal adenocarcinoma | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02885753 | Dec 2016 → Sep 2028 expected | colorectal neoplasm | Federation Francophone de Cancerologie Digestive | Recruiting | No outcome recorded |
| Phase 3 | NCT02394795 | May 2015 → Jan 2022 | colorectal cancer | Takeda | Completed | Met primary |
| Phase 3 | NCT02162563 | Jul 2014 → Jul 2022 | metastasis from malignant tumor of colon | Dutch Colorectal Cancer Group | Completed | Mixed |
| Phase 3 | NCT01910610 | Oct 2013 → Jul 2023 | colorectal cancer | GERCOR - Multidisciplinary Oncology Cooperative Group | Unknown | No outcome recorded |
| Phase 3 | NCT01627379 | May 2012 → May 2015 | esophageal squamous cell carcinoma | AIO-Studien-gGmbH | Terminated | Missed primary Stop: Business |
| Phase 3 | NCT01412957 | Nov 2011 → Jun 2014 | colorectal cancer | Amgen | Completed | Met primary |
| Phase 3 | NCT02818725 | Jun 2010 → Sep 2016 | infiltrating urothelial carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT01001377 | Feb 2010 → Feb 2013 | colorectal cancer | Amgen | Completed | Met primary |
| Phase 3 | NCT00820248 | Dec 2008 → May 2015 | head and neck cancer | NCIC Clinical Trials Group | Completed | Missed primary |
| Phase 3 | NCT00460265 | May 2007 → May 2010 | head and neck squamous cell carcinoma | Amgen | Completed | Missed primary |
| Phase 3 | NCT00389870 | Dec 2006 → ? | colorectal cancer | University of Leeds | Completed | Missed primary |
| Phase 3 | NCT00364013 | Aug 2006 → Aug 2009 | colorectal cancer | Amgen | Completed | Met primary |
| Phase 3 | NCT00339183 | Jun 2006 → Apr 2009 | colorectal cancer | Amgen | Completed | Mixed |
| Phase 3 | NCT00115765 | Jun 2005 → May 2007 | colorectal cancer | Amgen | Completed | Missed primary |
| Phase 3 | NCT00113763 | Jan 2004 → Oct 2008 | colorectal cancer, metastatic neoplasm | Amgen | Completed | Met primary |
| Phase 3 | NCT01142414 | — | head and neck squamous cell carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02301962 | Jul 2015 → Jun 2021 | cancer | Dr. Reddy's Laboratories Limited | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00853931 | Oct 2009 → Sep 2015 | colorectal cancer | British Columbia Cancer Agency | Completed | No outcome recorded |
| Comparator or background therapy35 trials | ||||||
| Phase 0 | NCT07318389 Background | Jun 2026 → Nov 2027 expected | colorectal cancer | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06011772 Background | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07829588 Comparator | Nov 2026 → Feb 2028 expected | colorectal cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07021898 Background | Aug 2025 → Aug 2028 expected | metastatic neoplasm | Erasca, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05747625 Background | May 2023 → Feb 2027 expected | head and neck squamous cell carcinoma, skin squamous cell carcinoma | Eben Rosenthal | Recruiting | No outcome recorded |
| Phase 1 | NCT05084859 Background | Nov 2021 → Oct 2022 | castration-resistant prostate carcinoma, colorectal cancer, non-small cell lung carcinoma | Biosplice Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05786924 Background | Apr 2023 → Jun 2028 expected | colorectal carcinoma, histiocytic and dendritic cell neoplasm, histiocytosis, metastatic malignant neoplasm in the brain +2 | Servier | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03384238 Background | Feb 2018 → Mar 2027 expected | pancreatic adenocarcinoma | George Poultsides | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03263429 Background | Aug 2017 → Aug 2023 | colorectal cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00867334 Comparator | Jun 2009 → Aug 2011 | colorectal cancer | Inova Health Care Services | Completed | No outcome recorded |
| Phase 2 | NCT05423197 Comparator | Jun 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07201519 Background | Jan 2026 → Feb 2028 expected | colorectal cancer, intrahepatic cholangiocarcinoma | Michael J Cavnar, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT06245356 Background | Mar 2025 → Oct 2026 expected | colorectal cancer, dihydropyrimidine dehydrogenase deficiency, gastroesophageal adenocarcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 2 | NCT06714357 Background | Mar 2025 → Dec 2026 expected | colorectal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 2 | NCT05576896 Background | Oct 2022 → Oct 2025 | colorectal cancer | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04787341 Comparator | Dec 2020 → Aug 2025 overdue | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Active not recruiting | Missed primary |
| Phase 2 | NCT04668976 Background | Nov 2020 → Dec 2023 | cholangiocarcinoma, colorectal cancer | Benaroya Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03693807 Background | Oct 2018 → Jun 2024 | cholangiocarcinoma, colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03164655 Background | Jul 2018 → Jul 2021 | metastasis from malignant tumor of colon | UNICANCER | Completed | Missed primary |
| Phase 2 | NCT04425239 Comparator | May 2018 → Jul 2021 | colorectal cancer | National Cancer Institute, Naples | Completed | No outcome recorded |
| Phase 2 | NCT03186326 Comparator | Apr 2018 → May 2022 | colorectal cancer | Federation Francophone de Cancerologie Digestive | Completed | Met primary |
| Phase 2 | NCT03069950 Background | Feb 2017 → May 2019 | colorectal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02980510 Comparator | Dec 2016 → Dec 2025 | colorectal cancer | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT02904031 Background | Jul 2016 → Nov 2019 | metastasis from malignant tumor of colon | Gruppo Oncologico del Nord-Ovest | Unknown | Met primary |
| Phase 2 | NCT02448810 Background | Jun 2015 → Feb 2017 | colorectal cancer | Baxalta now part of Shire | Terminated | Missed primary |
| Phase 2 | NCT01418742 Comparator | Aug 2011 → May 2013 | colorectal carcinoma | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00756444 Comparator | Oct 2008 → Mar 2012 | head and neck squamous cell carcinoma | Amgen | Completed | No outcome recorded |
| Phase 2/3 | NCT07509398 Background | Apr 2026 → Dec 2027 expected | colorectal cancer | Shanghai 10th People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05863195 Background | Apr 2024 → Jun 2029 expected | colorectal carcinoma, metastatic malignant neoplasm | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT03231722 Background | Sep 2017 → Jun 2022 | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Completed | Missed primary |
| Phase 3 | NCT04342676 Background | Mar 2017 → Aug 2019 | malignant colon neoplasm | Mansoura University | Completed | No outcome recorded |
| Phase 3 | NCT02314182 Background | Nov 2014 → Feb 2018 | rectum adenocarcinoma | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT00824785 Comparator | May 2008 → Feb 2013 | gastroesophageal cancer | Royal Marsden NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 4 | NCT02015923 Background | Dec 2013 → Jun 2019 | metastasis from malignant tumor of colon | Hospital Universitari de Bellvitge | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT04276090 Background | May 2020 → Jan 2022 | bile duct neoplasm, colorectal neoplasm | Michael J Cavnar, MD | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 17
| Date | Issuer | Release |
|---|---|---|
| 2025-01-17 | Amgen | Regulatory FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER amgen.com ↗ |
| 2023-10-22 | Amgen | Results AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER amgen.com ↗
Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). |
| 2023-10-16 | Amgen | Results AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023 amgen.com ↗
Pivotal Phase 3 CodeBreaK 300 Study Data Support LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) Combination in KRAS G12C-Mutated mCRC |
| 2023-08-03 | Amgen | Results AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS amgen.com ↗
Positive Top-Line Results for LUMAKRAS ® (Sotorasib) Plus Vectibix ® (Panitumumab) in Metastatic Colorectal Cancer |
| 2023-06-04 | Amgen | Results AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023 amgen.com ↗
LUMAKRAS Plus Vectibix ® (panitumumab) and FOLFIRI Combination Show ORR of 55% in Previously Treated KRAS G12C-Mutated Metastatic CRC |
| 2023-06-01 | Amgen | Results AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023 amgen.com ↗
Novel Combinations Show Encouraging Safety and Efficacy in Pre-Treated KRAS G12C-Mutated Metastatic CRC and First-Line NSCLC |
| 2022-09-12 | Amgen | Results LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER amgen.com ↗
We are thrilled to see these CodeBreaK 101 results, which show that LUMAKRAS plus Vectibix achieved a 30% confirmed objective response rate in patients with KRAS G12C-mutated metastatic colorectal cancer. |
| 2022-06-05 | Amgen | Results NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER amgen.com ↗ |
| 2021-09-16 | Amgen | Results LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer amgen.com ↗
These new data show that combining LUMAKRAS™ (sotorasib) with Vectibix ® (panitumumab), Amgen 's monoclonal antibody epidermal growth factor receptor (EGFR) inhibitor, demonstrated encouraging efficacy and safety. |
| 2017-06-29 | Amgen | Regulatory FDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer amgen.com ↗ |
| 2017-01-23 | Sumitomo Pharma America, Inc. | Results Sumitomo Dainippon Pharma Announces Clinical Data of Investigational Cancer Stemness Inhibitor Napabucasin were presented at 2017 ASCO GI Symposium sumitomo-pharma.com ↗
72 pts were enrolled, 48 pts were evaluable by RECIST of which 7 (15%) and 41 (85%) had 2 or ≥3 prior treatment lines, respectively. |
| 2016-10-10 | Amgen | Results New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin amgen.com ↗
The retrospective analysis of the PEAK study in mCRC patients with RAS wild-type primary tumors of left-sided origin showed that patients receiving Vectibix plus FOLFOX6 as first-line treatment achieved 43.4 months median overall survival (OS), an increase of 11.4 months when compared to FOLFOX6 plus bevacizumab. |
| 2016-01-23 | Amgen | Results Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer amgen.com ↗
The study met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC; n=377 total). |
| 2015-06-18 | Amgen | Results Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care amgen.com ↗
Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix ® (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. |
| 2015-04-06 | Amgen | Regulatory European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer amgen.com ↗
Amgen (NASDAQ: AMGN) today announced that the European Commission approved a new use of Vectibix ® (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). |
| 2015-02-27 | Amgen | Regulatory Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer amgen.com ↗
The CHMP recommendation is an important step toward increasing the treatment options for patients with this aggressive disease and helping improve outcomes in the European Union . |
| 2015-01-15 | Amgen | Results Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer amgen.com ↗
Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix ® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, in patients with wild-type RAS (absence of exons 2, 3, or 4 KRAS or NRAS mutations) metastatic colorectal cancer (mCRC). |
All press releases naming this drug 18 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 258 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | panitumumab | “Investigator's choice of standard first-line systemic therapy for initially unresectable colorectal cancer, including chemotherapy (e.g., FOLFOX, FOLFIRI, CAPOX) with or...” NCT07509398 ↗246“Treatment in this multicentric neoadjuvant pilot study consisted of panitumumab (9 mg/kg) for eight cycles q.3 weeks combined with four cycles of 5-fluorouracil, epidoxorubicin...” PMID 24827135 ↗ May 2014 “Per current SOC guidelines, EGFR inhibitors targeting driver mutations (e.g., RAS wild-type) will be administered as appropriate (FDA-approved agents such as Panitumumab for EGFR)” NCT07201519 ↗ “Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)” NCT04276090 ↗ “ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.” NCT06983743 ↗ “Anti-EGFR treatment with either Panitumumab (6 mg/kg IV over 60 minutes, Day 1) or Cetuximab” NCT06575127 ↗ “Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression” NCT01057017 ↗ “anti-EGFR monoclonal antibody (cetuximab 500 mg/m2 q2w or panitumumab 6 mg/kg q2w)” NCT06226857 ↗ “QL1203 (Vectibix® Biosimilar Candidate) and Panitumumab (EU-Vectibix®)” NCT07829588 ↗ “Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks” NCT06967155 ↗ “Subjects will receive Panitumumab plus cisplatin and 5FU” NCT00460265 ↗ |
| Known as | ABX-EGF | “Panitumumab (ABX-EGF) is the first fully human monoclonal antibody specific to the EGF receptor.” NCT00861120 ↗8“Drug: panitumumab (ABX-EGF)” NCT00091806 ↗ “Panitumumab (ABX-EGF)” NCT00425204 ↗ “Panitumumab (ABX-EGF)” NCT00425035 ↗ “ABX-EGF (panitumumab)” NCT00327119 ↗ |
| Known as | AMG 954 | “AMG 954/Panitumumab” NCT00352950 ↗ |
| Known as | EU-Vectibix | “QL1203 (Vectibix® Biosimilar Candidate) and Panitumumab (EU-Vectibix®)” NCT07829588 ↗ |
| Known as | PAN | “panitumumab (PAN) as initial treatment of elderly” PMID 37535876 ↗ Aug 2023 |
| Known as | panitumumab: Vectibix | “panitumumab: Vectibix” NCT01389414 ↗ |
| Known as | panitumumad | “EGFR antibodies panitumumad and cetuxiamb in case of KRAS wild-type tumors.” NCT02314182 ↗ |
| Known as | Panitumumbab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06011772 ↗ |
| Known as | Pmab | “In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX...” PMID 28633089 ↗ Jun 20173“receiving 5-fluoruracil/folinic acid ± panitumumab (Pmab) maintenance after Pmab + fluorouracil, folinic acid, and oxaliplatin induction” PMID 40736443 ↗ Oct 2025 “assessed the tolerance and complete response (CR) rate at 8 weeks of panitumumab (Pmab) combined with” PMID 37315583 ↗ Jun 2023 “Panitumumab (Pmab) 6 mg/kg, intravenous drip infusion (DIV)” NCT02337946 ↗ |
| Known as | Vectibix | “Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast...” NCT00933517 ↗5“Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma” NCT00879385 ↗ “Panitumumab (Vectibix) is a fully humanized monoclonal antibody directed against epidermal growth factor receptor (EGFr)” NCT00586443 ↗ “Panitumumab (Vectibix™) is approved by the FDA for the treatment of advanced colorectal cancer” NCT01061788 ↗ “Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]” NCT05468892 ↗ “Panitumumab (Vectibix®)” NCT01262183 ↗ |
| Known as | Vectibix (Panitumumab) | “Vectibix (Panitumumab)” NCT01320254 ↗3“Vectibix (Panitumumab)” NCT01374789 ↗ “Vectibix (panitumumab)” NCT07021898 ↗ “Vectibix (Panitumumab)” NCT01328171 ↗ |
| Known as | VectibixTM | “The purpose of this study is to test a new drug combination consisting of two drugs, vemurafenib (also known as ZelborafTM) and panitumumab (also known as VectibixTM).” NCT01791309 ↗ |
| Action | Inhibit | “Blocking this stimulus by blocking activation of EGFR with ABX-EGF” NCT00034346 ↗ |
| Modality | Monoclonal antibody | “ABX-EGF, a fully human monoclonal antibody against EGFR” NCT00034346 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT00083616 ↗ |
| Target | EGFR | “Panitumumab is a human monoclonal antibody targeting the epidermal growth factor receptor” PMID 34213592 ↗ Jul 2021 |